373 related articles for article (PubMed ID: 36522745)
1. Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer.
Kallenbach J; Atri Roozbahani G; Heidari Horestani M; Baniahmad A
Cell Biosci; 2022 Dec; 12(1):200. PubMed ID: 36522745
[TBL] [Abstract][Full Text] [Related]
2. Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.
Pungsrinont T; Sutter MF; Ertingshausen MCCM; Lakshmana G; Kokal M; Khan AS; Baniahmad A
Cell Biosci; 2020; 10():59. PubMed ID: 32351687
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype.
Kumari R; Jat P
Front Cell Dev Biol; 2021; 9():645593. PubMed ID: 33855023
[TBL] [Abstract][Full Text] [Related]
5. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells.
Schwarze SR; Shi Y; Fu VX; Watson PA; Jarrard DF
Oncogene; 2001 Dec; 20(57):8184-92. PubMed ID: 11781834
[TBL] [Abstract][Full Text] [Related]
6. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.
Roediger J; Hessenkemper W; Bartsch S; Manvelyan M; Huettner SS; Liehr T; Esmaeili M; Foller S; Petersen I; Grimm MO; Baniahmad A
Mol Cancer; 2014 Sep; 13():214. PubMed ID: 25216853
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer.
Kokal M; Mirzakhani K; Pungsrinont T; Baniahmad A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32650419
[TBL] [Abstract][Full Text] [Related]
8. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype.
Coppé JP; Rodier F; Patil CK; Freund A; Desprez PY; Campisi J
J Biol Chem; 2011 Oct; 286(42):36396-403. PubMed ID: 21880712
[TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1.
Collado M; Medema RH; Garcia-Cao I; Dubuisson ML; Barradas M; Glassford J; Rivas C; Burgering BM; Serrano M; Lam EW
J Biol Chem; 2000 Jul; 275(29):21960-8. PubMed ID: 10791951
[TBL] [Abstract][Full Text] [Related]
12. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
[TBL] [Abstract][Full Text] [Related]
13. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of AGR2 induces cellular senescence in prostate cancer cells.
Hu Z; Gu Y; Han B; Zhang J; Li Z; Tian K; Young CY; Yuan H
Carcinogenesis; 2012 Jun; 33(6):1178-86. PubMed ID: 22467239
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
16. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.
Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F
Cells; 2020 Jul; 9(7):. PubMed ID: 32630281
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone induces cellular senescence in prostate cancer cells through induction of DEC1.
Kotolloshi R; Mirzakhani K; Ahlburg J; Kraft F; Pungsrinont T; Baniahmad A
J Steroid Biochem Mol Biol; 2020 Jul; 201():105689. PubMed ID: 32360904
[TBL] [Abstract][Full Text] [Related]
18. Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications.
Carpenter VJ; Patel BB; Autorino R; Smith SC; Gewirtz DA; Saleh T
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188424. PubMed ID: 32956765
[TBL] [Abstract][Full Text] [Related]
19. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.
Liu J; Estes ML; Drazba JA; Liu H; Prayson R; Kondo S; Jacobs BS; Barnett GH; Barna BP
Oncogene; 2000 Feb; 19(5):661-9. PubMed ID: 10698511
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer.
Chambers CR; Ritchie S; Pereira BA; Timpson P
Mol Oncol; 2021 Dec; 15(12):3242-3255. PubMed ID: 34137158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
